The Developmental Center for Neuroregulation in Alcohol Dependence (CeNiAD) grew from the clinical observation that the CNS active generic CM adrenoreceptor (AR) antagonist prazosin reduced or eliminated alcohol drinking in veterans with posttraumatic stress disorder (PTSD) and comorbid alcohol dependence. Recently we demonstrated in placebo-controlled studies that prazosin reduces alcohol consumption in two animal models of alcohol dependence and in a human study in persons with alcohol dependence but without PTSD. Our clinical observation, our compelling prazosin preclinical and clinical treatment data, emerging neuroscience data implicating the CM AR in mechanisms of addiction, and the presence at VA Puget Sound and the University of Washington of a critical mass of faculty investigating alcohol dependence have led to the proposed developmental center. The CeNiAD has the following goals: (1) To create an interdisciplinary translational research team investigating oil AR and other neuroregulatory mechanisms and interventions in alcohol use disorders (ADD);(2) To establish the collaborations, facilities, research capabilities, preliminary findings, career development opportunities, intellectual milieu and planning process to justify an application for a future new Specialized P50 Alcohol Research Center. An Administrative Core will support the scientific mission, develop and coordinate career development of basic and clinical AUD investigators, provide biostatistics and data management support, and provide the planning process for a future P50 Center. A distinguished External Advisory Board will help guide the CeNiAD in these activities. There will be two first wave exploratory projects and two first wave pilot projects. Exploratory Project 1 addresses effects of pharmacologic reduction of noradrenergic signaling in alcohol ingestion in alcohol preferring rats. Exploratory Project 2 is a placebo-controlled prazosin trial in persons with co-occurring alcohol dependence and PTSD. Pilot Project 1 addresses prazosin effects on cue-induced alcohol craving in humans. Pilot Project 2 addresses prazosin effects on alcohol craving and consumption in military returnees from Iraq and Afghanistan with PTSD. A process for solicitation and review of especially relevant additional exploratory and pilot projects has been established to support a second wave of such projects in the second 2.5 years of the CeNiAD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Exploratory Grants (P20)
Project #
1P20AA017839-01
Application #
7547207
Study Section
Special Emphasis Panel (ZAA1-BB (80))
Program Officer
Egli, Mark
Project Start
2009-09-30
Project End
2011-08-31
Budget Start
2009-09-30
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$488,049
Indirect Cost
Name
Seattle Institute for Biomedical/Clinical Research
Department
Type
DUNS #
928470061
City
Seattle
State
WA
Country
United States
Zip Code
98108
Simpson, Tracy L; Malte, Carol A; Dietel, Bergetta et al. (2015) A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 39:808-17
Rasmussen, Dennis D; Kincaid, Carrie L; Froehlich, Janice C (2015) Prazosin + Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in P Rats with a Protracted History of Extensive Voluntary Alcohol Drinking, Dependence, and Multiple Withdrawals. Alcohol Clin Exp Res 39:1832-41
Rasmussen, Dennis D; Alexander, Laura; Malone, Julia et al. (2014) The ?2-adrenergic receptor agonist, clonidine, reduces alcohol drinking in alcohol-preferring (P) rats. Alcohol 48:543-9
Rasmussen, Dennis D; Beckwith, Lauren E; Kincaid, Carrie L et al. (2014) Combining the ?1 -adrenergic receptor antagonist, prazosin, with the ?-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. Alcohol Clin Exp Res 38:1532-9
Aversa, Laura H; Stoddard, Jill A; Doran, Neal M et al. (2013) Longitudinal analysis of the relationship between PTSD symptom clusters, cigarette use, and physical health-related quality of life. Qual Life Res 22:1381-9
O'Neil, Meghan L; Beckwith, Lauren E; Kincaid, Carrie L et al. (2013) The ?1-adrenergic receptor antagonist, doxazosin, reduces alcohol drinking in alcohol-preferring (P) Rats. Alcohol Clin Exp Res 37:202-12
Verplaetse, Terril L; Rasmussen, Dennis D; Froehlich, Janice C et al. (2012) Effects of prazosin, an ?1-adrenergic receptor antagonist, on the seeking and intake of alcohol and sucrose in alcohol-preferring (P) rats. Alcohol Clin Exp Res 36:881-6
Aversa, Laura H; Stoddard, Jill A; Doran, Neal M et al. (2012) PTSD and depression as predictors of physical health-related quality of life in tobacco-dependent veterans. J Psychosom Res 73:185-90
Harder, Laura H; Chen, Shuo; Baker, Dewleen G et al. (2011) The influence of posttraumatic stress disorder numbing and hyperarousal symptom clusters in the prediction of physical health status in veterans with chronic tobacco dependence and posttraumatic stress disorder. J Nerv Ment Dis 199:940-5